Displaying drugs 2451 - 2475 of 3602 in total
AGI-1096
AGI-1096 is a novel oral antioxidant and selective anti-inflammatory agent that is being developed to address the accelerated inflammation of grafted blood vessels, known as transplant arteritis, common in chronic organ transplant rejection.
Investigational
XMT-1001
XMT-1001 is a polymer-based prodrug of camptothecin (CPT), a well-characterized topoisomerase I inhibitor with potent anti-tumor activity. It is a water-soluble macromolecular conjugate of camptothecin (CPT). In this novel CPT pro-drug, CPT is conjugated with a 70 kDa biodegradable hydrophilic polyacetal, poly (1-hydroxymethylene hydroxylmethylformal). XMT-1001 has demonstrated an improved therapeutic...
Investigational
CTS-1027
CTS-1027 has been used in trials studying the treatment of Hepatitis C and Chronic Hepatitis C Virus Infection.
Experimental
Investigational
CTT-1057
CTT-1057 is under investigation in clinical trial NCT03427476 (CTT1057, a Small Molecular Inhibitor of PSMA, as a Novel Imaging Agent of Neovascularization in Renal Cell Carcinoma).
Investigational
TERN-101
TERN-101 is under investigation in clinical trial NCT04328077 (LIFT Study: A Safety, Tolerability, Efficacy, and Pharmacokinetics Study of TERN-101 in Subjects With Non-cirrhotic Non-alcoholic Steatohepatitis (NASH)).
Investigational
TALL-104
Investigational
PPI-1040
Investigational
NP-10679
Investigational
RBIO-101
RBIO-101 is a recombinant adeno-associated virus vector encoding human CYP4V2 protein.
Investigational
EDIT-101
EDIT-101 is a recombinant adeno-associated virus pseudotyped with serotype 5 viral capsid encoding CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats associated protein 9) gene editing constructs.
Investigational
ORY-1001
Investigational
ONCOS-102
Investigational
CRA_10433
Experimental
ADX-10061
ADX10061 is a potent, selective antagonist of the dopamine D1 receptor. It is developed by Addex Pharmaceuticals for the treatment of nicotine dependence.
Investigational
Matched Iupac: … (5S)-5-(2,3-dihydro-1-benzofuran-7-yl)-3-methyl-8-nitro-2,3,4,5-tetrahydro-1H-3-benzazepin-7-ol …
ONCOS‐102
Investigational
VB10.16
VB10.16 is a novel therapeutic antigen-presenting cell-targeting DNA vaccine developed to treat HPV16-positive cancers. It is composed of three parts, one encodes the E6/E7 fusion protein of human papillomavirus (HPV) type 16 (HPV16), a dimerization entity, and the part encoding a protein that specifically binds to antigen-presenting cells (APCs).
Investigational
BN104
Investigational
KB105
Investigational
Ornidazole
Ornidazole has been used in trials studying the prevention of Elective Colorectal Surgery.
Investigational
Matched Mixtures name: … ORNISASIN 500 MG/500 MG FILM TABLET, 10 ADET ... ORCIPOL 500 MG/500 MG FILM TABLET, 10 ADET ... SIPROFORTE 500 MG/ 500 MG FILM TABLET , 10 ADET …
Matched Products: … ORNITOP 500 MG FILM TABLET, 10 ADET ... BITERAL 500 MG FILM KAPLI TABLET, 10 ADET ... ALBITROL 500 MG FİLM KAPLI TABLET, 10 ADET …
Matched Products: … ORNITOP 500 MG FILM TABLET, 10 ADET ... BITERAL 500 MG FILM KAPLI TABLET, 10 ADET ... ALBITROL 500 MG FİLM KAPLI TABLET, 10 ADET …
ACG-801
Investigational
Osbond acid
Experimental
Sitamaquine
Sitamaquine (WR-6026) is an orally active 8-aminoquinoline analog in development by the Walter Reed Army Institute, in collaboration with GlaxoSmithKline (formerly SmithKline Beecham), for the potential treatment of visceral leishmaniasis.
Investigational
Matched Iupac: … N-[6-(diethylamino)hexyl]-6-methoxy-4-methylquinolin-8-amine …
Matched Description: … Sitamaquine (WR-6026) is an orally active 8-aminoquinoline analog in development by the Walter Reed Army …
Matched Description: … Sitamaquine (WR-6026) is an orally active 8-aminoquinoline analog in development by the Walter Reed Army …
Displaying drugs 2451 - 2475 of 3602 in total